BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 09 Aug 2026
CagriSema: The GLP-1 and Amylin Combination With an FDA Decision Expected Before Year-End
Novo Nordisk's CagriSema — a fixed-dose combination of semaglutide 2.4 mg and the long-acting amylin analogue cagrilintide — is now under FDA review for obesity, with a decision anticipated in Q4 2026. This briefing sets out the mechanism, the pivotal REDEFINE trial results, the REDEFINE-4 head-to-head complication, and what the compound's regulatory pathway means for UK research-procurement teams.
Read briefing →
Research Pipeline
BPC-157: What the Evidence Base Actually Shows — Mechanism, Human Data, and Post-PCAC Regulatory Position
BPC-157 is among the most discussed peptides in regenerative research, yet its human clinical evidence remains critically thin. Following the FDA PCAC's narrow 8-6 recommendation in July 2026, this spotlight examines what the peer-reviewed literature actually shows, what the rulemaking timeline means for procurement, and what UK research professionals need to understand about its current legal status.
08 Aug 2026
Research Pipeline
Retatrutide's TRIUMPH Programme: Five Positive Phase 3 Readouts, a BLA Confirmed for Q1 2027 — What the Data Mean for Research Procurement
Eli Lilly has completed five positive Phase 3 studies for retatrutide, its first-in-class GIP/GLP-1/glucagon triple agonist, with topline TRIUMPH-2 and TRIUMPH-3 results released on 23 July 2026. The company has confirmed a Biologics Licence Application to the FDA in Q1 2027, marking the clearest regulatory timeline yet for the most efficacious agent in the GLP-1 class. For research procurement teams, the data package now available reframes how this investigational peptide should be sourced…
07 Aug 2026
Regulatory & Policy
PCAC July 2026: Six Peptides Cleared, FDA Staff Overruled — What the Vote Results Mean for Research Procurement
The FDA's Pharmacy Compounding Advisory Committee voted on 23–24 July 2026 to recommend six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the Section 503A Bulks List, overriding its own career scientists on every favourable decision. Emideltide was the sole rejection. Formal rulemaking now begins, and none of the six can be legally compounded until that process concludes — a timeline that may extend to 2027 or 2028.
06 Aug 2026
Industry & Community
Orforglipron and the Non-Peptide GLP-1: Why a Small-Molecule Approval Matters to the Peptide Research Sector
Eli Lilly's orforglipron (Foundayo) was FDA-approved in April 2026 as the first oral small-molecule GLP-1 receptor agonist — a compound that is structurally not a peptide. Its MHRA review is under way, with a potential UK marketing authorisation in late 2026. For research-procurement professionals, the distinction matters: orforglipron's approval reframes the competitive landscape for peptide-based GLP-1 manufacturing and signals where the next phase of obesity pharmacology is heading.
05 Aug 2026
Reputational Risks
Compounded GLP-1s and the Additive Problem: What a Tirzepatide-B12 Impurity Study Means for Research Quality Standards
A peer-reviewed study has identified a novel, widespread chemical impurity in mass-compounded tirzepatide products blended with vitamin B12 — a finding that reinforces wider concerns about additive contamination in peptide supply chains and carries direct lessons for research-grade quality assurance.
04 Aug 2026
Regulatory & Policy
The Five Peptides Heading to PCAC Before February 2027 — and Why Analysts Consider Them a Harder Case Than July's Slate
With the July PCAC votes now concluded, attention turns to the five peptides scheduled for a follow-on Pharmacy Compounding Advisory Committee review before the end of February 2027: injectable GHK-Cu, Cathelicidin (LL-37), Dihexa acetate, Melanotan II, and PEG-MGF. Each carries a more complex evidentiary or safety profile than its July predecessors, and none yet has a clear 503A compounding pathway.
03 Aug 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With Four Decades of Longevity Research — and a Fresh PCAC Recommendation
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from bovine pineal gland extract, studied for over 40 years for telomerase activation, melatonin regulation, and geroprotection. On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee recommended it for inclusion on the 503A Bulks List — a significant regulatory milestone that places the compound closer to US clinical access than at any previous point, while substantive evidentiary gaps remain.
02 Aug 2026
Research Pipeline
Thymosin Alpha-1: The Immunomodulatory Peptide With Decades of Clinical Data — and a Complicated Regulatory Position
Thymosin alpha-1 (Tα1) has been approved as Zadaxin in more than 35 countries for chronic hepatitis B and studied across over 80 clinical trials — making it one of the most clinically documented peptides available. Yet it remains unapproved in the US and carries no MHRA marketing authorisation in the UK, leaving research-procurement teams navigating a jurisdiction-dependent patchwork of access and legal constraints.
01 Aug 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Bid: What the Deal Signals for Global Peptide Manufacturing Capacity
Samsung Biologics launched a CHF 1.46 billion all-cash tender offer for Swiss peptide CDMO PolyPeptide Group on 20 July 2026 — the largest-ever Korean biopharma acquisition. The move accelerates a consolidation wave in peptide contract manufacturing driven by sustained GLP-1 demand, and carries direct implications for research-procurement teams monitoring API supply-chain resilience.
31 Jul 2026
Regulatory & Policy
FDA's 503B Bulks List Comment Period Closes Today on GLP-1 Compounding Ban — What Comes Next
Today, 30 July 2026, marks the final day for public comments on the FDA's proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Once the docket closes, the agency will move toward a final determination that would strip 503B outsourcing facilities of the last legal pathway for large-scale GLP-1 compounding — with direct consequences for research procurement and the broader peptide supply chain.
30 Jul 2026
Research Pipeline
CJC-1295 and Ipamorelin: The GHRH/GHRP Combination That Sits Outside the PCAC Process — What the Evidence Shows
While the FDA's Pharmacy Compounding Advisory Committee dominated peptide headlines this week, CJC-1295 and Ipamorelin occupy a distinct regulatory position: neither compound was among the twelve peptides removed from Category 2 in April 2026, nor is either scheduled for PCAC review. This briefing examines their mechanisms, the state of the clinical evidence, and what their current status means for UK research procurement.
29 Jul 2026